Bristol-Myers Squibb Company (BMY)
NYSE: BMY · IEX Real-Time Price · USD
44.85
+0.15 (0.34%)
At close: Apr 26, 2024, 4:00 PM
44.90
+0.05 (0.11%)
After-hours: Apr 26, 2024, 7:59 PM EDT
BMY Revenue
Bristol-Myers Squibb Company had revenue of $45.53B in the twelve months ending March 31, 2024, down -0.68% year-over-year. Revenue in the quarter ending March 31, 2024 was $11.87B with 4.66% year-over-year growth. In the year 2023, Bristol-Myers Squibb Company had annual revenue of $45.01B, a decrease of -2.50%.
Revenue (ttm)
$45.53B
Revenue Growth
-0.68%
P/S Ratio
2.00
Revenue / Employee
$1,335,308
Employees
34,100
Market Cap
90.90B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 45.01B | -1.15B | -2.50% |
Dec 31, 2022 | 46.16B | -226.00M | -0.49% |
Dec 31, 2021 | 46.39B | 3.87B | 9.09% |
Dec 31, 2020 | 42.52B | 16.37B | 62.62% |
Dec 31, 2019 | 26.15B | 3.58B | 15.89% |
Dec 31, 2018 | 22.56B | 1.79B | 8.59% |
Dec 31, 2017 | 20.78B | 1.35B | 6.94% |
Dec 31, 2016 | 19.43B | 2.87B | 17.31% |
Dec 31, 2015 | 16.56B | 681.00M | 4.29% |
Dec 31, 2014 | 15.88B | -506.00M | -3.09% |
Dec 31, 2013 | 16.39B | -1.24B | -7.01% |
Dec 31, 2012 | 17.62B | -3.62B | -17.05% |
Dec 31, 2011 | 21.24B | 1.76B | 9.03% |
Dec 31, 2010 | 19.48B | 676.00M | 3.59% |
Dec 31, 2009 | 18.81B | 1.09B | 6.17% |
Dec 31, 2008 | 17.72B | 2.10B | 13.43% |
Dec 31, 2007 | 15.62B | -591.00M | -3.65% |
Dec 31, 2006 | 16.21B | -2.40B | -12.88% |
Dec 31, 2005 | 18.61B | -775.00M | -4.00% |
Dec 31, 2004 | 19.38B | 727.00M | 3.90% |
Dec 31, 2003 | 18.65B | 2.45B | 15.09% |
Dec 31, 2002 | 16.21B | -1.84B | -10.18% |
Dec 31, 2001 | 18.04B | 506.00M | 2.89% |
Dec 31, 2000 | 17.54B | 1.04B | 6.28% |
Dec 31, 1999 | 16.50B | 1.44B | 9.57% |
Dec 31, 1998 | 15.06B | -1.64B | -9.82% |
Dec 31, 1997 | 16.70B | 1.64B | 10.86% |
Dec 31, 1996 | 15.07B | 1.30B | 9.43% |
Dec 31, 1995 | 13.77B | 1.78B | 14.88% |
Dec 31, 1994 | 11.98B | 571.00M | 5.00% |
Dec 31, 1993 | 11.41B | 257.00M | 2.30% |
Dec 31, 1992 | 11.16B | 585.00M | 5.53% |
Dec 31, 1991 | 10.57B | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
CVS Health | 357.78B |
Cigna | 195.27B |
HCA Healthcare | 64.97B |
GSK | 38.39B |
Medtronic | 32.32B |
Gilead Sciences | 27.12B |
Boston Scientific | 14.24B |
Regeneron Pharmaceuticals | 13.12B |
BMY News
- 2 days ago - CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma - Business Wire
- 3 days ago - Bristol Myers Cuts Full-Year Earnings Forecast, Launches Cost Cuts - Barrons
- 3 days ago - Bristol Myers Squibb beats on revenue, launches $1.5 billion cost cuts as it posts quarterly loss - CNBC
- 3 days ago - Bristol Myers Squibb reports narrower-than-expected first-quarter loss, sales top estimates - Market Watch
- 3 days ago - Bristol Myers posts quarterly loss, revenue rises 5% - Reuters
- 3 days ago - Bristol Myers Squibb Reports First Quarter Financial Results for 2024 - Business Wire
- 6 days ago - Bristol Myers Squibb and Cellares reach $380 mln supply deal for CAR-T therapies - Reuters
- 6 days ago - Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster - Business Wire